*Feature Image : NY Post, Reuters
Definium Therapeutics just shook both biotech and mental health spaces in a big way. The company’s shares [NASDAQ: DFTX] surged more than 50% after its LSD-based depression treatment delivered strong late-stage trial results, signaling a potential shift in how we treat major depressive disorder. The drug, known as DT120, is a pharmaceutical version of LSD designed for controlled clinical use. In a Phase 3 trial, a single dose significantly reduced depression symptoms compared to a placebo after six weeks. That alone is striking, especially in a field where most treatments take weeks or…
